Movement Alert｜EVEREST MED Intraday Rise 5.03% in Regular Trading, mRNA platform global clinical development expectations remain elevated

Market Focus10-21

On October 21, EVEREST MED rose 5.03% in Regular Trading, trading at HK$35.36, with turnover of HK$53.62 million.

The move coincided with continued market focus on the company’s in-house mRNA platform and expectations for faster global clinical development.

Recent disclosures show EVEREST MED appointed two former Moderna core scientists, with their roles centered on advancing U.S. clinical development for the mRNA platform in coordination with the China R&D team. The company has also reported initial human data for personalized therapeutic cancer vaccine EVM16, while off-the-shelf tumor-associated antigen vaccine EVM14 is progressing in clinical development, reinforcing signals that the platform has entered the clinical validation stage.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment